3737 — Zhongzhi Pharmaceutical Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapContrarian

Market Cap
HK$794.51m
Enterprise Value
HK$822.74m
Revenue
CNY2.21bn

Annual income statement for Zhongzhi Pharmaceutical Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,604	1,747	1,826	2,050	2,215
Cost of Revenue
Gross Profit	991	1,064	1,070	1,221	1,285
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,431	1,678	1,689	1,834	2,061
Operating Profit	172	68.9	137	215	154
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	167	61.8	131	208	147
Provision for Income Taxes
Net Income After Taxes	139	52.4	107	164	96.1
Minority Interest
Net Income Before Extraordinary Items
Net Income	139	52.1	106	163	95.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	139	52.1	106	163	95.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.167	0.062	0.125	0.192	0.112
Dividends per Share